Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 754 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Estrogens Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 28, 2026, 1:00 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
4,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
72
States / cities
Daphne, Alabama • Bakersfield, California • Fullerton, California + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Clinical Trial of Trametes Versicolor in Women With Breast Cancer

NCT00680667
View directory record Official record
Conditions
Breast Cancer
Interventions
Coriolus versicolor extract
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota • Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 2 Interventional

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

NCT02760030
View directory record Official record
Conditions
Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Fulvestrant, Laboratory Biomarker Analysis, Palbociclib, Questionnaire Administration, Aromatase Inhibitors
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Edgewood, Kentucky • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 28, 2026, 1:00 PM EDT
Recruiting Phase 2 Interventional

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

NCT07466498
View directory record Official record
Conditions
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Terminated Phase 2 Interventional

Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

NCT00303615
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fluoxymesterone 10 mg, Anastrozole 1 mg
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Early Phase 1 Interventional

Broccoli Sprout Extract in Treating Patients With Breast Cancer

NCT01753908
View directory record Official record
Conditions
Ductal Breast Carcinoma, Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Postmenopausal, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Broccoli Sprout Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Early Phase 1 Interventional

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

NCT03962647
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer
Interventions
2-Week Ketogenic Diet, Letrozole
Dietary Supplement · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 2 Interventional

Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

NCT00018343
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
estrogen
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 90 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Lakewood, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 28, 2026, 1:00 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108
View directory record Official record
Conditions
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
Interventions
Elacestrant, Abemaciclib
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Fullerton, California • Los Angeles, California • Urbana, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed No phase listed Observational

Susceptibility to Breast Cancer

NCT00004565
View directory record Official record
Conditions
Breast Cancer, Healthy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 28, 2026, 1:00 PM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

NCT00141557
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 28, 2026, 1:00 PM EDT
Suspended Not applicable Interventional

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

NCT02993068
View directory record Official record
Conditions
BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma
Interventions
Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Recruiting Early Phase 1 Interventional

FES BPET-DBT in Newly Diagnosed Breast Cancer

NCT05659797
View directory record Official record
Conditions
Breast Cancer
Interventions
BPET/DBT imaging, 18F-FES
Device · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 3 Interventional

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

NCT00803335
View directory record Official record
Conditions
Pelvic Organ Prolapse, Vaginal Atrophy
Interventions
Vaginal conjugated estrogen cream 0.5gm, Vaginal conjugated estrogen cream 1.0gm
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 28, 2026, 1:00 PM EDT
Withdrawn Not applicable Interventional

The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence

NCT01123135
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Vaginal ERT, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

NCT00767520
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane + Dasatinib, Exemestane + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Fountain Valley, California • Riverside, California • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

NCT05054374
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
Interventions
Mirdametinib, Fulvestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 28, 2026, 1:00 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Resistance Training and Sex Hormone Concentrations During the Menstrual Cycle

NCT04163380
View directory record Official record
Conditions
Women's Health
Interventions
Resistance Training
Behavioral
Lead sponsor
Southern Illinois University Edwardsville
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Edwardsville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Results available

Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

NCT00956813
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
flaxseed, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
107
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 28, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

NCT01594398
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions
entinostat, Erlotinib, Exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 28, 2026, 1:00 PM EDT